Cover Image

Cost of disease progression among US patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

Aim: The objectives were to investigate the differences in per patient per month (PPPM) healthcare resource utilization (HCRU) and costs among commercially insured and Medicare Advantage patients with human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer (mBC) who experi...

Full description

Saved in:

Bibliographic Details
Main Authors:	Clara Lam (Author), Brandon Diessner (Author), Katherine Andrade (Author), Sydnie Stackland (Author), Leah Park (Author), Sandhya Mehta (Author), Feng Lin (Author), Winghan Jackie Kwong (Author)
Format:	Book
Published:	Becaris Publishing Limited, 2024-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Real-World Treatment Patterns and Economic Burden Following First-Line Trastuzumab in Patients with Metastatic Gastric Cancer in the USA
by: Afsaneh Barzi, et al.
Published: (2023)

Utilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinoma
by: Chan Shen, et al.
Published: (2022)

Treatment Patterns and Adverse Event-Related Hospitalization Among Patients with Epidermal Growth Factor Receptor (EGFR)-Mutated Metastatic Non-small Cell Lung Cancer After Treatment with EGFR Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy Regimens
by: Elizabeth Marrett, et al.
Published: (2023)

Effect of Ferric Carboxymaltose Versus Low-Dose Intravenous Iron Therapy and Iron Sucrose on the Total Cost of Care in Patients with Iron Deficiency Anemia: A US Claims Database Analysis
by: Winghan Jacqueline Kwong, et al.
Published: (2024)

Oestrogen receptor β5 and epidermal growth factor receptor synergistically promote lung cancer progression
by: Yuquan Bai, et al.
Published: (2018)

Metastatic Squamous Cell Carcinoma from Lung Adenocarcinoma after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy
by: Hyung Kyu Park, et al.
Published: (2017)

Metastatic dermatosis in breast carcinoma on adjuvant trastuzumab: Is skin a sanctuary site in human epidermal growth factor receptor-2-amplified disease?
by: Amit Sehrawat, et al.
Published: (2018)

Metastatic Progression and Tumour Heterogeneity
Published: (2020)

A clinical systematic literature review of treatments among patients with advanced and/or metastatic human epidermal growth factor receptor 2 positive breast cancer
by: Kerigo Ndirangu, et al.
Published: (2024)

Retrospective claims analysis of best supportive care costs and survival in a US metastatic renal cell population
by: Henk HJ, et al.
Published: (2013)

Case Report: Multi-targeted therapy in the treatment of severe toxic epidermal necrolysis
by: Elaine Yi Lee Kwong, et al.
Published: (2024)

Epidermal Growth Factor Receptor immunohistochemical expression in hepatocellular carcinoma without Epidermal Growth Factor Receptor exons 18-21 mutations
by: Nikolova Dafina, et al.
Published: (2022)

Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States
by: Neelima Denduluri, et al.
Published: (2022)

Epidermal growth factor receptor: Role in human cancer
by: Prashanth Rajaram, et al.
Published: (2017)

Modulation of Pathological Pain by Epidermal Growth Factor Receptor
by: Jazlyn P. Borges, et al.
Published: (2021)

Vandetanib induced phototoxic reaction progressed to toxic epidermal necrolysis
by: Busra Demirbag Gul, et al.
Published: (2022)

Fatal Metastatic Cutaneous Squamous Cell Carcinoma Evolving from a Localized Verrucous Epidermal Nevus
by: Hassan Riad, et al.
Published: (2013)

Transcriptional effects of inhibiting epidermal growth factor receptor in keratinocytes
by: Alix Gazel, et al.
Published: (2013)

Nuclear epidermal growth factor receptor as a therapeutic target
by: Benjamin Atwell, et al.
Published: (2023)

Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatinand irinotecan-based chemotherapy and biologics in the US
by: Victoria Federico Paly, et al.
Published: (2024)

Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
by: Connor O'Leary, et al.
Published: (2020)

Extracranial metastatic oligodendroglioma with molecular progression, case presentation
by: Nour Kurdi, et al.
Published: (2024)

Nanodelivery Systems Targeting Epidermal Growth Factor Receptors for Glioma Management
by: Sathishbabu Paranthaman, et al.
Published: (2020)

Toxic epidermal necrolysis secondary to timolol, ketorolac, and moxifloxacin eyedrops
by: Sandhya George, et al.
Published: (2014)

Toxic epidermal necrolysis secondary to timolol, ketorolac, and moxifloxacin eyedrops
by: Sandhya George, et al.
Published: (2014)

Cabozantinib for progressive metastatic medullary thyroid cancer: a review
by: Colombo JR, et al.
Published: (2014)

Six cases of purpuric eruptions induced by epidermal growth factor receptor inhibitors
by: Tomoko Hiraiwa, et al.
Published: (2018)

Idiopathic extensive acanthosis nigricans with a variant of the epidermal growth factor receptor
by: Amena Alkeswani, BS, et al.
Published: (2020)

Dermatological side effects of epidermal growth factor receptor inhibitors: 'Pride' complex
by: Bhushan Madke, et al.
Published: (2014)

The roles of epidermal growth factor receptor (EGFR) inhibitors in the management of lung cancer
by: Ashwaq Al Olayan, et al.
Published: (2012)

Desensitization by Different Strategies of Epidermal Growth Factor Receptor and ErbB4
by: Hideyuki Yamamoto, et al.
Published: (2014)

Immune responses to epidermal growth factor receptor (EGFR) and their application for cancer treatment
by: Tetsuro Sasada, et al.
Published: (2016)

Cardiotoxicity of Epidermal Growth Factor Receptor 2-Targeted Drugs for Breast Cancer
by: ZiYan Yang, et al.
Published: (2021)

Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling
by: Naoyuki Nishiya, et al.
Published: (2019)

Mouse Syngeneic Melanoma Model with Human Epidermal Growth Factor Receptor Expression
by: Tatiana A. Slastnikova, et al.
Published: (2022)

The Role of Epidermal Growth Factor Receptor Family of Receptor Tyrosine Kinases in Mediating Diabetes-Induced Cardiovascular Complications
by: Bara A. Shraim, et al.
Published: (2021)

The Effects of Anlotinib Combined with Chemotherapy following Progression on Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor-Positive Metastatic Breast Cancer
by: Ting Xu, et al.
Published: (2024)

Adalimumab for Sintilimab-Induced Toxic Epidermal Necrolysis in a Patient with Metastatic Gastric Malignancy: A Case Report and Literature Review
by: Zhang L, et al.
Published: (2023)

It may cost an arm and a leg: workers value and occupational fatality rates in the U.S.
by: Leah S. Klos, et al.
Published: (2021)

Mucin Production Correlates with Dual Expression of Epidermal Growth Factor Receptor and Its Ligand the Epidermal Growth Factor in Non-Small Cell Lung Cancer
by: Rancés Blanco, et al.
Published: (2017)